Passage Bio Business Model Canvas
Business Model Canvas for a Gene Therapy Biotech: Strategy, Partners, Revenue Streams
Unlock the full strategic blueprint behind Passage Bio’s business model in a concise, actionable Business Model Canvas that maps value propositions, key partners, revenue streams, and growth levers. Perfect for investors, advisors, and founders seeking competitive insight and execution-ready analysis. Purchase the complete, editable canvas to benchmark strategy and accelerate decision-making.
Partnerships
Academic research alliances
Collaborations with universities and medical schools fuel target discovery and translational science for rare CNS disorders, supplying disease models, biomarkers and natural history datasets that accelerate candidate selection. Co-development agreements can de-risk early biology and share up to 40% of preclinical costs. Joint publications bolster scientific credibility and strengthen regulatory dossiers for IND filings.
Vector CDMOs & GMP manufacturers
Specialized AAV CDMOs provide scalable, GMP-compliant vector production with process development, analytics and release testing under GMP; as of 2024 these partners increasingly support technology transfer across sites to ensure reproducible quality. Flexible capacity reservations allow matching batch sizes to orphan-disease demand and mitigate supply risk for low-volume programs.
CROs & clinical trial networks
CROs and clinical trial networks manage multi-center trials, logistics, and data integrity for Passage Bio, coordinating complex site operations and regulatory compliance across regions. Rare disease networks accelerate patient identification and enrollment in a space of 7,000+ rare diseases affecting ~300 million people worldwide, improving recruitment velocity. Centralized imaging, PK/PD, and biomarker labs standardize endpoints and data harmonization. These partnerships compress timelines and enhance trial quality.
Patient advocacy organizations
Patient advocacy organizations support patient finding, education, and trial awareness, with over 7,000 rare disease groups globally (Global Genes, 2024). They inform meaningful endpoint selection and burden-of-disease insights, co-create materials that improve adherence and informed consent, and their registries supply longitudinal outcomes data used by regulators and payers.
- Patient identification & recruitment
- Endpoint & burden insights
- Co-created adherence/consent materials
- Registries for longitudinal regulatory/payer evidence
IP licensors & capsid technology providers
Access to novel AAV capsids, promoters and delivery enhancers expands CNS tropism and payload efficiency; by 2024 over 1,000 engineered capsid variants had been reported, boosting transduction and reducing peripheral exposure. Licensing secures freedom to operate and accelerates platform evolution; option structures align cash outlays with milestones (IND, POC, BLA) and de‑risk spend. Cross‑licenses enable combination strategies and new indications, unlocking collaboration value.
- Capsid breadth: >1,000 engineered variants (2024)
- Milestone alignment: upfronts minimized via options
- Freedom to operate: licenses reduce IP litigation risk
- Cross‑license: opens combos and indication expansion
Collaboration cuts preclinical costs 40% and scales CNS gene therapy with 1,000+ capsids
Collaborations with academia, CDMOs, CROs and patient groups accelerate CNS gene therapy, sharing up to 40% of preclinical costs and leveraging >1,000 engineered capsids (2024). Rare-disease networks (7,000+ groups) and registries cover ~300 million affected worldwide, speeding recruitment and regulatory evidence generation.
| Partner | Role | 2024 metric |
|---|---|---|
| Academia | Models, biomarkers | IND-strengthening |
| CDMOs | GMP AAV production | Tech transfer trend (2024) |
| CROs | Trials & data | Faster enrollment |
| Patient groups | Recruitment, registries | 7,000+ groups; 300M people |
| Licensors | Capsids/IP | >1,000 variants (2024) |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Passage Bio aligning its gene‑therapy R&D, clinical development and commercialization strategy across the 9 BMC blocks; covers customer segments, value propositions, key partnerships, channels, revenue and funding paths, plus competitive advantages and risks—suitable for investor presentations and strategic decision-making.
Customizable Excel Spreadsheet
High-level view of Passage Bio’s business model with editable cells, clarifying how its gene-therapy pipeline, R&D partnerships, and commercialization/reimbursement strategies address rare-disease treatment gaps and investor decision points.
Activities
AAV capsid & construct engineering
Designing AAV capsids and constructs for CNS targeting, cell specificity, and expression control is core to Passage Bio’s R&D, with promoter selection and codon optimization used to tune therapeutic windows. In vitro and in vivo screens refine potency and safety, supporting iterative design cycles that lower immunogenicity and off-target risks. By 2024 there were two FDA-approved AAV therapies, underscoring clinical translation potential and rigorous safety benchmarking.
Preclinical pharmacology & toxicology
Robust preclinical studies establish dose, biodistribution and toxicology in relevant models, typically including rodent and non-rodent species as per FDA guidance. Biomarker development connects molecular correction to functional outcomes using validated PD and surrogate markers. GLP toxicology packages are assembled to support IND submissions. Translational plans map animal NOAEL and exposure data to first-in-human dosing via allometric and PK/PD modeling.
GMP manufacturing & CMC scale-up
Process development improves AAV yield, purity and batch-to-batch consistency to meet clinical and commercial demands, reducing downstream costs and time to release. Robust release assays validate identity, potency and safety, enabling confident lot release for trials. Comparability protocols de-risk manufacturing changes across scales while comprehensive CMC documentation underpins regulatory approvals and lifecycle management.
Clinical development & regulatory
Designing adaptive early-phase trials accelerates proof-of-concept and dose finding; Passage Bio leverages orphan, RMAT and Breakthrough pathways where eligible (pathways active in 2024). Continuous regulator engagement aligns endpoints and CMC plans, while independent data monitoring and pharmacovigilance ensure patient safety throughout development.
- Adaptive early-phase trials
- Orphan/RMAT/Breakthrough pursuit (2024 active)
- Regulator alignment on endpoints & manufacturing
- Ongoing DMC & pharmacovigilance
Market access & medical affairs
Health economic models quantify lifetime value and QALYs to justify one-time therapy pricing, citing precedents like Zolgensma at $2.125M and Luxturna at $850,000; outcomes-based agreements with payers (pay-for-performance, annuity) mitigate budget impact; KOL education and peer-reviewed publications build adoption readiness; patient support programs handle navigation and long-term follow-up.
- HE Models: QALYs, WTP $100k–$150k
- Pricing refs: Zolgensma $2.125M; Luxturna $850k
- Contracts: outcomes-based, annuity
- Support: navigation, long-term monitoring
CNS AAV: capsid/promoter tuning, GLP-to-IND and CMC scale-up enable clinical translation
Designing CNS‑targeted AAV capsids/constructs with promoter tuning and iterative in vitro/in vivo screening drives potency and safety; by 2024 two FDA AAV approvals validated clinical translation. Rigorous GLP preclinical packages and PK/PD modeling inform IND and first‑in‑human dosing. CMC scale‑up and release assays secure clinical supply. Adaptive trials, orphan/RMAT pathways and HE models support pricing and payer arrangements.
| Activity | 2024 metric | Key fact |
|---|---|---|
| R&D | 2 FDA AAV approvals (by 2024) | Clinical translation validated |
| Preclinical | GLP tox standard | IN D support |
| CMC | Scale‑up to clinical batches | Comparability required |
| HE/Pricing | Zolgensma $2.125M; Luxturna $850k | Outcomes/annuity deals |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the actual Passage Bio Business Model Canvas, not a mockup—what you see is a direct extract from the final deliverable. After purchase you'll receive this exact file with all sections included. It arrives fully formatted and editable, ready for immediate use in Word and Excel.
Business Model Canvas for a Gene Therapy Biotech: Strategy, Partners, Revenue Streams
Unlock the full strategic blueprint behind Passage Bio’s business model in a concise, actionable Business Model Canvas that maps value propositions, key partners, revenue streams, and growth levers. Perfect for investors, advisors, and founders seeking competitive insight and execution-ready analysis. Purchase the complete, editable canvas to benchmark strategy and accelerate decision-making.
Partnerships
Academic research alliances
Collaborations with universities and medical schools fuel target discovery and translational science for rare CNS disorders, supplying disease models, biomarkers and natural history datasets that accelerate candidate selection. Co-development agreements can de-risk early biology and share up to 40% of preclinical costs. Joint publications bolster scientific credibility and strengthen regulatory dossiers for IND filings.
Vector CDMOs & GMP manufacturers
Specialized AAV CDMOs provide scalable, GMP-compliant vector production with process development, analytics and release testing under GMP; as of 2024 these partners increasingly support technology transfer across sites to ensure reproducible quality. Flexible capacity reservations allow matching batch sizes to orphan-disease demand and mitigate supply risk for low-volume programs.
CROs & clinical trial networks
CROs and clinical trial networks manage multi-center trials, logistics, and data integrity for Passage Bio, coordinating complex site operations and regulatory compliance across regions. Rare disease networks accelerate patient identification and enrollment in a space of 7,000+ rare diseases affecting ~300 million people worldwide, improving recruitment velocity. Centralized imaging, PK/PD, and biomarker labs standardize endpoints and data harmonization. These partnerships compress timelines and enhance trial quality.
Patient advocacy organizations
Patient advocacy organizations support patient finding, education, and trial awareness, with over 7,000 rare disease groups globally (Global Genes, 2024). They inform meaningful endpoint selection and burden-of-disease insights, co-create materials that improve adherence and informed consent, and their registries supply longitudinal outcomes data used by regulators and payers.
- Patient identification & recruitment
- Endpoint & burden insights
- Co-created adherence/consent materials
- Registries for longitudinal regulatory/payer evidence
IP licensors & capsid technology providers
Access to novel AAV capsids, promoters and delivery enhancers expands CNS tropism and payload efficiency; by 2024 over 1,000 engineered capsid variants had been reported, boosting transduction and reducing peripheral exposure. Licensing secures freedom to operate and accelerates platform evolution; option structures align cash outlays with milestones (IND, POC, BLA) and de‑risk spend. Cross‑licenses enable combination strategies and new indications, unlocking collaboration value.
- Capsid breadth: >1,000 engineered variants (2024)
- Milestone alignment: upfronts minimized via options
- Freedom to operate: licenses reduce IP litigation risk
- Cross‑license: opens combos and indication expansion
Collaboration cuts preclinical costs 40% and scales CNS gene therapy with 1,000+ capsids
Collaborations with academia, CDMOs, CROs and patient groups accelerate CNS gene therapy, sharing up to 40% of preclinical costs and leveraging >1,000 engineered capsids (2024). Rare-disease networks (7,000+ groups) and registries cover ~300 million affected worldwide, speeding recruitment and regulatory evidence generation.
| Partner | Role | 2024 metric |
|---|---|---|
| Academia | Models, biomarkers | IND-strengthening |
| CDMOs | GMP AAV production | Tech transfer trend (2024) |
| CROs | Trials & data | Faster enrollment |
| Patient groups | Recruitment, registries | 7,000+ groups; 300M people |
| Licensors | Capsids/IP | >1,000 variants (2024) |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Passage Bio aligning its gene‑therapy R&D, clinical development and commercialization strategy across the 9 BMC blocks; covers customer segments, value propositions, key partnerships, channels, revenue and funding paths, plus competitive advantages and risks—suitable for investor presentations and strategic decision-making.
Customizable Excel Spreadsheet
High-level view of Passage Bio’s business model with editable cells, clarifying how its gene-therapy pipeline, R&D partnerships, and commercialization/reimbursement strategies address rare-disease treatment gaps and investor decision points.
Activities
AAV capsid & construct engineering
Designing AAV capsids and constructs for CNS targeting, cell specificity, and expression control is core to Passage Bio’s R&D, with promoter selection and codon optimization used to tune therapeutic windows. In vitro and in vivo screens refine potency and safety, supporting iterative design cycles that lower immunogenicity and off-target risks. By 2024 there were two FDA-approved AAV therapies, underscoring clinical translation potential and rigorous safety benchmarking.
Preclinical pharmacology & toxicology
Robust preclinical studies establish dose, biodistribution and toxicology in relevant models, typically including rodent and non-rodent species as per FDA guidance. Biomarker development connects molecular correction to functional outcomes using validated PD and surrogate markers. GLP toxicology packages are assembled to support IND submissions. Translational plans map animal NOAEL and exposure data to first-in-human dosing via allometric and PK/PD modeling.
GMP manufacturing & CMC scale-up
Process development improves AAV yield, purity and batch-to-batch consistency to meet clinical and commercial demands, reducing downstream costs and time to release. Robust release assays validate identity, potency and safety, enabling confident lot release for trials. Comparability protocols de-risk manufacturing changes across scales while comprehensive CMC documentation underpins regulatory approvals and lifecycle management.
Clinical development & regulatory
Designing adaptive early-phase trials accelerates proof-of-concept and dose finding; Passage Bio leverages orphan, RMAT and Breakthrough pathways where eligible (pathways active in 2024). Continuous regulator engagement aligns endpoints and CMC plans, while independent data monitoring and pharmacovigilance ensure patient safety throughout development.
- Adaptive early-phase trials
- Orphan/RMAT/Breakthrough pursuit (2024 active)
- Regulator alignment on endpoints & manufacturing
- Ongoing DMC & pharmacovigilance
Market access & medical affairs
Health economic models quantify lifetime value and QALYs to justify one-time therapy pricing, citing precedents like Zolgensma at $2.125M and Luxturna at $850,000; outcomes-based agreements with payers (pay-for-performance, annuity) mitigate budget impact; KOL education and peer-reviewed publications build adoption readiness; patient support programs handle navigation and long-term follow-up.
- HE Models: QALYs, WTP $100k–$150k
- Pricing refs: Zolgensma $2.125M; Luxturna $850k
- Contracts: outcomes-based, annuity
- Support: navigation, long-term monitoring
CNS AAV: capsid/promoter tuning, GLP-to-IND and CMC scale-up enable clinical translation
Designing CNS‑targeted AAV capsids/constructs with promoter tuning and iterative in vitro/in vivo screening drives potency and safety; by 2024 two FDA AAV approvals validated clinical translation. Rigorous GLP preclinical packages and PK/PD modeling inform IND and first‑in‑human dosing. CMC scale‑up and release assays secure clinical supply. Adaptive trials, orphan/RMAT pathways and HE models support pricing and payer arrangements.
| Activity | 2024 metric | Key fact |
|---|---|---|
| R&D | 2 FDA AAV approvals (by 2024) | Clinical translation validated |
| Preclinical | GLP tox standard | IN D support |
| CMC | Scale‑up to clinical batches | Comparability required |
| HE/Pricing | Zolgensma $2.125M; Luxturna $850k | Outcomes/annuity deals |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the actual Passage Bio Business Model Canvas, not a mockup—what you see is a direct extract from the final deliverable. After purchase you'll receive this exact file with all sections included. It arrives fully formatted and editable, ready for immediate use in Word and Excel.
Description
Business Model Canvas for a Gene Therapy Biotech: Strategy, Partners, Revenue Streams
Unlock the full strategic blueprint behind Passage Bio’s business model in a concise, actionable Business Model Canvas that maps value propositions, key partners, revenue streams, and growth levers. Perfect for investors, advisors, and founders seeking competitive insight and execution-ready analysis. Purchase the complete, editable canvas to benchmark strategy and accelerate decision-making.
Partnerships
Academic research alliances
Collaborations with universities and medical schools fuel target discovery and translational science for rare CNS disorders, supplying disease models, biomarkers and natural history datasets that accelerate candidate selection. Co-development agreements can de-risk early biology and share up to 40% of preclinical costs. Joint publications bolster scientific credibility and strengthen regulatory dossiers for IND filings.
Vector CDMOs & GMP manufacturers
Specialized AAV CDMOs provide scalable, GMP-compliant vector production with process development, analytics and release testing under GMP; as of 2024 these partners increasingly support technology transfer across sites to ensure reproducible quality. Flexible capacity reservations allow matching batch sizes to orphan-disease demand and mitigate supply risk for low-volume programs.
CROs & clinical trial networks
CROs and clinical trial networks manage multi-center trials, logistics, and data integrity for Passage Bio, coordinating complex site operations and regulatory compliance across regions. Rare disease networks accelerate patient identification and enrollment in a space of 7,000+ rare diseases affecting ~300 million people worldwide, improving recruitment velocity. Centralized imaging, PK/PD, and biomarker labs standardize endpoints and data harmonization. These partnerships compress timelines and enhance trial quality.
Patient advocacy organizations
Patient advocacy organizations support patient finding, education, and trial awareness, with over 7,000 rare disease groups globally (Global Genes, 2024). They inform meaningful endpoint selection and burden-of-disease insights, co-create materials that improve adherence and informed consent, and their registries supply longitudinal outcomes data used by regulators and payers.
- Patient identification & recruitment
- Endpoint & burden insights
- Co-created adherence/consent materials
- Registries for longitudinal regulatory/payer evidence
IP licensors & capsid technology providers
Access to novel AAV capsids, promoters and delivery enhancers expands CNS tropism and payload efficiency; by 2024 over 1,000 engineered capsid variants had been reported, boosting transduction and reducing peripheral exposure. Licensing secures freedom to operate and accelerates platform evolution; option structures align cash outlays with milestones (IND, POC, BLA) and de‑risk spend. Cross‑licenses enable combination strategies and new indications, unlocking collaboration value.
- Capsid breadth: >1,000 engineered variants (2024)
- Milestone alignment: upfronts minimized via options
- Freedom to operate: licenses reduce IP litigation risk
- Cross‑license: opens combos and indication expansion
Collaboration cuts preclinical costs 40% and scales CNS gene therapy with 1,000+ capsids
Collaborations with academia, CDMOs, CROs and patient groups accelerate CNS gene therapy, sharing up to 40% of preclinical costs and leveraging >1,000 engineered capsids (2024). Rare-disease networks (7,000+ groups) and registries cover ~300 million affected worldwide, speeding recruitment and regulatory evidence generation.
| Partner | Role | 2024 metric |
|---|---|---|
| Academia | Models, biomarkers | IND-strengthening |
| CDMOs | GMP AAV production | Tech transfer trend (2024) |
| CROs | Trials & data | Faster enrollment |
| Patient groups | Recruitment, registries | 7,000+ groups; 300M people |
| Licensors | Capsids/IP | >1,000 variants (2024) |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Passage Bio aligning its gene‑therapy R&D, clinical development and commercialization strategy across the 9 BMC blocks; covers customer segments, value propositions, key partnerships, channels, revenue and funding paths, plus competitive advantages and risks—suitable for investor presentations and strategic decision-making.
Customizable Excel Spreadsheet
High-level view of Passage Bio’s business model with editable cells, clarifying how its gene-therapy pipeline, R&D partnerships, and commercialization/reimbursement strategies address rare-disease treatment gaps and investor decision points.
Activities
AAV capsid & construct engineering
Designing AAV capsids and constructs for CNS targeting, cell specificity, and expression control is core to Passage Bio’s R&D, with promoter selection and codon optimization used to tune therapeutic windows. In vitro and in vivo screens refine potency and safety, supporting iterative design cycles that lower immunogenicity and off-target risks. By 2024 there were two FDA-approved AAV therapies, underscoring clinical translation potential and rigorous safety benchmarking.
Preclinical pharmacology & toxicology
Robust preclinical studies establish dose, biodistribution and toxicology in relevant models, typically including rodent and non-rodent species as per FDA guidance. Biomarker development connects molecular correction to functional outcomes using validated PD and surrogate markers. GLP toxicology packages are assembled to support IND submissions. Translational plans map animal NOAEL and exposure data to first-in-human dosing via allometric and PK/PD modeling.
GMP manufacturing & CMC scale-up
Process development improves AAV yield, purity and batch-to-batch consistency to meet clinical and commercial demands, reducing downstream costs and time to release. Robust release assays validate identity, potency and safety, enabling confident lot release for trials. Comparability protocols de-risk manufacturing changes across scales while comprehensive CMC documentation underpins regulatory approvals and lifecycle management.
Clinical development & regulatory
Designing adaptive early-phase trials accelerates proof-of-concept and dose finding; Passage Bio leverages orphan, RMAT and Breakthrough pathways where eligible (pathways active in 2024). Continuous regulator engagement aligns endpoints and CMC plans, while independent data monitoring and pharmacovigilance ensure patient safety throughout development.
- Adaptive early-phase trials
- Orphan/RMAT/Breakthrough pursuit (2024 active)
- Regulator alignment on endpoints & manufacturing
- Ongoing DMC & pharmacovigilance
Market access & medical affairs
Health economic models quantify lifetime value and QALYs to justify one-time therapy pricing, citing precedents like Zolgensma at $2.125M and Luxturna at $850,000; outcomes-based agreements with payers (pay-for-performance, annuity) mitigate budget impact; KOL education and peer-reviewed publications build adoption readiness; patient support programs handle navigation and long-term follow-up.
- HE Models: QALYs, WTP $100k–$150k
- Pricing refs: Zolgensma $2.125M; Luxturna $850k
- Contracts: outcomes-based, annuity
- Support: navigation, long-term monitoring
CNS AAV: capsid/promoter tuning, GLP-to-IND and CMC scale-up enable clinical translation
Designing CNS‑targeted AAV capsids/constructs with promoter tuning and iterative in vitro/in vivo screening drives potency and safety; by 2024 two FDA AAV approvals validated clinical translation. Rigorous GLP preclinical packages and PK/PD modeling inform IND and first‑in‑human dosing. CMC scale‑up and release assays secure clinical supply. Adaptive trials, orphan/RMAT pathways and HE models support pricing and payer arrangements.
| Activity | 2024 metric | Key fact |
|---|---|---|
| R&D | 2 FDA AAV approvals (by 2024) | Clinical translation validated |
| Preclinical | GLP tox standard | IN D support |
| CMC | Scale‑up to clinical batches | Comparability required |
| HE/Pricing | Zolgensma $2.125M; Luxturna $850k | Outcomes/annuity deals |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the actual Passage Bio Business Model Canvas, not a mockup—what you see is a direct extract from the final deliverable. After purchase you'll receive this exact file with all sections included. It arrives fully formatted and editable, ready for immediate use in Word and Excel.
